Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
In the fourth installment of our ‘One Year Later’ series we focus on lenacapavir and how science is breaking through formidable barriers in understanding HIV and how to prevent it, just as the infrastructure for delivering groundbreaking technology is defunded and destabilized.
Blog Post
This third installment of our ‘One Year Later’ series examines this administration’s sustained assault on the research enterprise. What has unfolded is a 365-day cascade of policy, programmatic and, financial actions that threaten US leadership and the scientific ecosystem responsible for lifesaving breakthroughs.
Blog Post
The second piece in AVAC’s ‘One Year Later’ series is out. From cuts to HIV vaccine research to attacks on ACIP and Gavi, we break down how ideology is undermining evidence and why global health depends on defending science.
showing 1-10 of 1172
In the fourth installment of our ‘One Year Later’ series we focus on lenacapavir and how science is breaking through formidable barriers in understanding HIV and how to prevent it, just as the infrastructure for delivering groundbreaking technology is defunded and destabilized.
This third installment of our ‘One Year Later’ series examines this administration’s sustained assault on the research enterprise. What has unfolded is a 365-day cascade of policy, programmatic and, financial actions that threaten US leadership and the scientific ecosystem responsible for lifesaving breakthroughs.
The second piece in AVAC’s ‘One Year Later’ series is out. From cuts to HIV vaccine research to attacks on ACIP and Gavi, we break down how ideology is undermining evidence and why global health depends on defending science.
AVAC’s ‘One Year Later’ series reflects on the tumultuous events of the past 365 days across five global health issues. First up: how the foreign aid freeze and abuse of executive power are costing lives.
The US foreign assistance budget, if enacted, would restore some global health funds in a broader context of uncertainty, as US bilateral “America First” health MoUs advance without transparent plans for implementation or accountability. At the same time, abrupt reversals by the US Department of Health and Human Services of troubling health policy decisions underscore the Administration’s instability. Meanwhile, momentum around lenacapavir continues, recently approved by Brazil and with additional funding from Unitaid to reach more populations in South Africa and Zambia.
On January 20, join us and Jeanne Marrazzo, IDSA CEO and AVAC board member, for The Future of HIV Prevention: A People’s Research Agenda for Speed, Scale and Equity, a webinar exploring the PRA’s people-centered framework, what the PRA tracks, why it matters and what’s at stake.
The assault on vaccine policy and confidence intensified this week as the US overhauled its childhood immunization schedule. Beyond the US, 14 countries have now signed bilateral health agreements with the US under the America First Global Health Strategy. At the same time, the US President signed a new executive order withdrawing the US from and defunding over 60 international organizations and treaties. And Germany reportedly plans to cut its funding by half for the World Health Organization’s Hub for Pandemic and Epidemic Intelligence.
As we look to the year ahead, we start by taking stock of the profound disruptions of 2025 and how the field responded. With immense challenges and historic opportunities ahead, we are making resolutions for the new year and sharing resources to advance our collective work in the months to come.
The Lancet journal ended the year with a provocative editorial – 2025: an annus horribilis for health in the USA. But sadly, it was not just in the US; it has been a year of chaos and disruption globally. This 49th issue of Global Health Watch looks back—like many news stories this week—across 2025 to highlight the most consequential decisions, disruptions, and debates that defined the year and will continue to shape what comes next.
Prevention Option:
This week the UNAIDS board approved a new Global AIDS Strategy and launched a formal review of the agency’s future; turmoil at the NIH continues over gain-of-function research; and the scientific community rallies around the Infectious Diseases Society of America’s (IDSA) appointment of Jeanne Marrazzo as its chief executive officer. Also, the UK regulatory agency approved lenacapavir for PrEP (LEN) marking its seventh regulatory approval in just six months.
Prevention Option:
showing 1-10 of 1172
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.